Delineating and eradicating cardiovascular inflammageing
Sector: Hospital • Location: Netherlands
Source: EU Funding & Tenders Portal
Atherosclerotic cardiovascular disease remains a leading global cause of morbidity and mortality, driven by inflammageing: a chronic, age-related inflammatory state accelerating atherosclerosis via epigenetic dysregulation in bone marrow immune cells, particularly hematopoietic stem and progenitor cells (HSPCs). Despite therapeutic advances, the precise mechanisms linking inflammageing to atherosc
- Status
- Prospective
- Sector
- Hospital, Nuclear
- Location
- Netherlands
- Updated
- 19 Nov 2026
- Source
- EU Funding & Tenders Portal
ConstructChat
Ask ConstructChat about Delineating and eradicating cardiovascular inflammageing
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | forthcoming |
Taiyo status | Prospective |
Taiyo last update | 2026-11-19 |
Contact
| Not available for this record. |
Description
Description | Atherosclerotic cardiovascular disease remains a leading global cause of morbidity and mortality, driven by inflammageing: a chronic, age-related inflammatory state accelerating atherosclerosis via epigenetic dysregulation in bone marrow immune cells, particularly hematopoietic stem and progenitor cells (HSPCs). Despite therapeutic advances, the precise mechanisms linking inflammageing to atherosclerosis remain underexplored, necessitating innovative approaches to address this escalating health burden in aging populations. The DEFLAME Program, a cross-disciplinary bioengineering initiative led by Prof. Dr. Willem Mulder, is aimed at delineating the heterogeneous mechanisms of cardiovascular inflammageing across bone marrow niches to guide development of precision mRNA immunotherapy for this insidious process. Leveraging MarrowMap, a novel quantitative tool to map immune cell metabolism across multiple bone marrow niches in mouse models, and our proprietary apolipoprotein nanoparticle (aNP) mRNA delivery platform, DEFLAME integrates nanomedicine, nuclear medicine, hematopoiesis, cardiovascular immunology and multi-omics to achieve two objectives: O1 To longitudinally and spatially characterize inflammageing in atherosclerosis-accelerated immune aging, myocardial infarction, and intermittent cholesterol exposure models. O2 To develop aNP-mRNA-based cytokine and checkpoint-directed immunotherapies targeting myeloid (progenitor) cells, with translational evaluation in human cell models. By combining expertise in nanomedicine, innate immunity, and cardiovascular disease, this high-risk, high-gain ERC Advanced Grant Program seeks to reshape our understanding of immune aging and deliver innovative immunotherapeutics with potential applications beyond cardiovascular disease, including cancer and neurodegenerative disorders, fostering breakthroughs for healthy aging. |
Location
Country | Netherlands |
Source
Source | EU Funding & Tenders Portal |
URL |
More Details
Record type | Project |
Sector | Hospital, Nuclear |
Article published date | 2026-10-15 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project
More Hospital projects in Netherlands
- OSKAR
- The NL Digital Hospital
- Rosalind Franklin Biotechnology Centre, Delft, Netherlands
- HALIX cGMP Biopharmaceutical Facility, Leiden
- Fujifilm’s Cell Culture Media Manufacturing Facility, Netherlands
- SHINE Medical Isotope Production Facility, Veendam, Netherlands
- Bristol Myers Squibb’s New CAR-T Cell Therapy Facility, Leiden, Netherlands
- Celtic Medical
